Linker stability influences the anti-tumor activity of acetazolamide-drug conjugates for the therapy of renal cell carcinoma

Journal of Controlled Release

Volumn 246, Issue , 2017, Pages 39-45

  Dal Corso, Alberto ^a   Neri, Dario ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

Drug release; Renal cell carcinoma; Small molecule drug conjugates; Targeted pro drugs; Therapy studies; Tumor targeting

Indexed keywords

AMINO ACIDS; CARBONIC ANHYDRASE; CELLS; CONTROLLED DRUG DELIVERY; CYTOLOGY; INFRARED DEVICES; MAMMALS; MOLECULES; PEPTIDES; SULFUR COMPOUNDS; THERMOGRAPHY (IMAGING); TUMORS;

DRUG RELEASE; RENAL CELL CARCINOMA; SMALL-MOLECULE DRUGS; TARGETED PRO-DRUGS; THERAPY STUDIES; TUMOR TARGETING;

TARGETED DRUG DELIVERY;

ACETAZOLAMIDE; ALANINE; ANTIBODY DRUG CONJUGATE; ARGININE; BRENTUXIMAB VEDOTIN; CARBONATE DEHYDRATASE IX; CITRULLINE; DIPEPTIDE; LYSINE; SORAFENIB; SUNITINIB; VALINE; ANTINEOPLASTIC AGENT; CARBONATE DEHYDRATASE INHIBITOR; OLIGOPEPTIDE; VEDOTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; COMPARATIVE STUDY; DRUG CONJUGATION; DRUG POTENCY; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL CELL CARCINOMA CELL LINE; SERUM; TUMOR MODEL; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; ENZYMOLOGY; KIDNEY; KIDNEY TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; RENAL CELL CARCINOMA; TUMOR CELL LINE;

ACETAZOLAMIDE; ANIMALS; ANTINEOPLASTIC AGENTS; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASE IX; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; KIDNEY; KIDNEY NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; OLIGOPEPTIDES;

EID: 85006959898     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2016.11.023     Document Type: Article

References (56)

1. [1] Bosslet, K., Straub, R., Blumrich, M., Czech, J., Gerken, M., Sperker, B., Kroemer, H.K., Gesson, J.P., Koch, M., Monneret, C., Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res. 58 (1998), 1195–1201.
2. [2] Cao, Q., Li, Z.-B., Chen, K., Wu, Z., He, L., Neamati, N., Chen, X., Evaluation of biodistribution and anti-tumor effect of a dimeric RGD peptide-paclitaxel conjugate in mice with breast cancer. Eur. J. Nucl. Med. Mol. Imaging 35 (2008), 1489–1498.
3. 11C-labelled docetaxel in cancer patients. Eur. J. Nucl. Med. Mol. Imaging 37 (2010), 1950–1958.
4. [4] Alley, S.C., Okeley, N.M., Senter, P.D., Antibody-drug conjugates: targeted drug delivery for cancer. Curr. Opin. Chem. Biol. 14 (2010), 529–537.
5. [5] Gerber, H.-P., Koehnb, F.E., Abraham, R.T., The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics. Nat. Prod. Rep. 30 (2013), 625–639.
6. [6] Chari, R.V.J., Miller, M.L., Widdison, W.C., Antibody-drug conjugates: an emerging concept in cancer therapy. Angew. Chem. Int. Ed. 53 (2014), 3796–3827.
7. [7] Chu, Y.-W., Polson, A., Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia. Future Oncol. 9 (2013), 355–368.
8. [8] Mould, D.R., Sweeney, K.R.D., The pharmacokinetics and pharmacodynamics of monoclonal antibodies–mechanistic modeling applied to drug development. Curr. Opin. Drug Discov. Devel. 10 (2007), 84–96.
9. [9] Pastuskovas, C.V., Mundo, E.E., Williams, S.P., Nayak, T.K., Ho, J., Ulufatu, S., Clark, S., Ross, S., Cheng, E., Parsons-Reponte, K., Cain, G., Van Hoy, M., Majidy, N., Bheddah, S., dela Cruz Chuh, J., Kozak, K.R., Lewin-Koh, N., Nauka, P., Bumbaca, D., Sliwkowski, M., Tibbitts, J., Theil, F.-P., Fielder, P.J., Khawli, L.A., Boswell, C.A., Effects of anti-VEGF on pharmacokinetics, biodistribution, and ttumor penetration of trastuzumab in a preclinical breast cancer model. Mol. Cancer Ther. 11 (2012), 752–762.
10. [10] Donaghy, H., Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. mAbs 8 (2016), 659–671.
11. [11] Boghaert, E.R., Khandke, K.M., Sridharan, L., Dougher, M., DiJoseph, J.F., Kunz, A., Hamann, P.R., Moran, J., Chaudhary, I., Damle, N.K., Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 microl) blood samples. Cancer Chemother. Pharmacol. 61 (2008), 1027–1035.
12. [12] Wei, C., Zhang, G., Clark, T., Barletta, F., Tumey, L.N., Rago, B., Hansel, S., Han, X., Where did the linker-payload go? A quantitative investigation on the destination of the releasedlinker-payload from an antibody-drug conjugate with a maleimide linker in plasma. Anal. Chem., 88, 2016 (4979–486).
13. [13] Casi, G., Neri, D., Antibody-drug conjugates and small molecule-drug conjugates: opportunities and challenges for the development of selective anticancer cytotoxic agents. J. Med. Chem. 58 (2015), 8751–8761.
14. [14] Dennis, M.S., Jin, H.K., Dugger, D., Yang, R.H., McFarland, L., Ogasawara, A., Williams, S., Cole, M.J., Ross, S., Schwall, R., Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res. 67 (2007), 254–261.
15. [15] Vlashi, E., Sturgis, J.E., Thomas, M., Low, P.S., Real time, noninvasive imaging and quantitation of the accumulation of ligand-targeted drugs into receptor-expressing solid tumors. Mol. Pharm. 6 (2009), 1868–1875.
16. [16] Kularatne, S.A., Wang, K., Santhapuram, H.K.R., Low, P.S., Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand. Mol. Pharm. 6 (2009), 780–789.
17. [17] Xia, W., Low, P.S., Folate-targeted therapies for cancer. J. Med. Chem. 53 (2010), 6811–6824.
18. [18] Vlahov, I.R., Leamon, C.P., Engineering folate-drug conjugates to target cancer: from chemistry to clinic. Bioconjug. Chem. 23 (2012), 1357–1369.
19. [19] Kularatne, S.A., Venkatesh, C., Santhapuram, H.-K.R., Wang, K., Vaitilingam, B., Henne, W.A., Low, P.S., Synthesis and biological analysis of prostate-specific membrane antigen-targeted anticancer prodrugs. J. Med. Chem. 53 (2010), 7767–7777.
20. [20] Engel, J.B., Schally, A.V., Dietl, J., Rieger, L., Hönig, A., Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones. Mol. Pharm. 4 (2007), 652–658.
21. [21] Srinivasarao, M., Galliford, C.V., Low, P.S., Principles in the design of ligand-targeted cancer therapeutics and imaging agents. Nat. Rev. Drug Discov. 14 (2015), 203–219.
22. [22] Thiry, A., Dogne, J.M., Masereel, B., Supuran, C.T., Targeting tumor-associated carbonic anhydrase IX in cancer therapy. Trends Pharmacol. Sci. 27 (2006), 566–573.
23. [23] Pastorekova, S., Zavada, J., Carbonic anhydrase IX (CA IX) as a potential target for cancer therapy. Cancer Ther. 2 (2004), 245–262.
24. [24] Supuran, C.T., Inhibition of carbonic anhydrase IX as a novel anticancer mechanism. World J. Clin. Oncol. 7 (2012), 98–103.
25. [25] Wykoff, C.C., Beasley, N.J., Watson, P.H., Turner, K.J., Pastorek, J., Sibtain, A., Wilson, G.D., Turley, H., Talks, K.L., Maxwell, P.H., Pugh, C.W., Ratcliffe, P.J., Harris, A.L., Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 60 (2000), 7075–7083.
26. [26] van Schaijk, F.G., Oosterwijk, E., Molkenboer-Kuenen, J.D., Soede, A.C., McBride, B.J., Goldenberg, D.M., Oyen, W.J., Corstens, F.H., Boerman, O.C., Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models. J. Nucl. Med. 46 (2005), 495–501.
27. [27] Lv, P.-C., Putt, K.S., Low, P.S., Evaluation of nonpeptidic ligand conjugates for SPECT imaging of hypoxic and carbonic anhydrase IX-expressing cancers. Bioconjug. Chem. 27 (2016), 1762–1769.
28. [28] Lloyd, M.C., Cunningham, J.J., Bui, M.M., Gillies, R.J., Brown, J.S., Gatenby, R.A., Darwinian dynamics of intratumoral heterogeneity: not solely random mutations but also variable environmental selection forces. Cancer Res. 76 (2016), 3136–3144.
29. [29] Petrul, H.M., Schatz, C.A., Kopitz, C.C., Adnane, L., McCabe, T.J., Trail, P., Ha, S., Chang, Y.S., Voznesensky, A., Ranges, G., Tamburini, P.P., Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9. Mol. Cancer Ther. 11 (2012), 340–349.
30. [30] Krall, N., Pretto, F., Decurtins, W., Bernardes, G.J.L., Supuran, C.T., Neri, D., A small-molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors. Angew. Chem. Int. Ed. 53 (2014), 4231–4235.
31. [31] Cazzamalli, S., Dal Corso, A., Neri, D., Acetazolamide serves as selective delivery vehicle for dipeptide-linked drugs to renal cell carcinoma. Mol. Cancer Ther., 2016, 10.1158/1535-7163.MCT-16-0283.
32. [32] Krall, N., Pretto, F., Neri, D., A bivalent small molecule-drug conjugate directed against carbonic anhydrase IX can elicit complete tumour regression in mice. Chem. Sci. 5 (2014), 3640–3644.
33. [33] Krall, N., Pretto, F., Mattarella, M., Müller, C., Neri, D., A 99mTc-labeled ligand of carbonic anhydrase IX selectively targets renal cell carcinoma in vivo. J. Nucl. Med. 57 (2016), 943–949.
34. [34] Perrino, E., Steiner, M., Krall, N., Bernardes, G.J.L., Pretto, F., Casi, G., Neri, D., Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids. Cancer Res. 74 (2014), 2569–2578.
35. [35] Gébleux, R., Wulhfard, S., Casi, G., Neri, D., Antibody format and drug release rate determine the therapeutic activity of noninternalizing antibody-drug conjugates. Mol. Cancer Ther. 14 (2015), 2606–2612.
36. [36] Brülisauer, L., Gauthier, M.A., Leroux, J.-C., Disulfide-containing parenteral delivery systems and their redox-biological fate. J. Control. Release 195 (2014), 147–154.
37. [37] Bander, N.H., Antibody-drug conjugate target selection: critical factors. Methods Mol. Biol. 1045 (2013), 29–40.
38. [38] Xu, S., Internalization, trafficking, intracellular processing and actions of antibody-drug conjugates. Pharm. Res. 32 (2015), 3577–3583.
39. [39] Yoo, B., Ma, K., Zhang, L., Burns, A., Sequeira, S., Mellinghoff, I., Brennan, C., Wiesner, U., Bradbury, M.S., Ultrasmall dual-modality silica nanoparticle drug conjugates: design, synthesis, and characterization. Bioorg. Med. Chem. 15 (2015), 7119–7130.
40. [40] Doronina, S.O., Toki, B.E., Torgov, M.Y., Mendelsohn, B.A., Cerveny, C.G., Chace, D.F., DeBlanc, R.L., Gearing, R.P., Bovee, T.D., Siegall, C.B., Francisco, J.A., Wahl, A.F., Meyer, D.L., Senter, P.D., Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol. 21 (2003), 778–784.
41. [41] Dubowchik, G.M., Firestone, R.A., Padilla, L., Willner, D., Hofstead, S.J., Mosure, K., Knipe, J.O., Lasch, S.J., Trail, P.A., Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug. Chem. 13 (2002), 855–869.
42. [42] Wichert, M., Krall, N., Decurtins, W., Franzini, R.M., Pretto, F., Schneider, P., Neri, D., Scheuermann, J., Dual-display of small molecules enables the discovery of ligand pairs and facilitates affinity maturation. Nat. Chem. 7 (2015), 241–249.
43. [43] Fischer, S., Gillessen, S., Rothermundt, C., Sequence of treatment in locally advanced and metastatic renal cell carcinoma. Transl. Androl. Urol. 4 (2015), 310–325.
44. 125I]Iodo-sunitinib. Bioorg. Med. Chem. Lett. 22 (2012), 2850–2855.
45. 11C]Sorafenib: radiosynthesis and preclinical evaluation in tumor-bearing mice of a new TKI-PET tracer. Nucl. Med. Biol. 40 (2013), 488–497.
46. [46] Higgins, G.S., O'Cathail, S.M., Muschel, R.J., McKenna, W.G., Drug radiotherapy combinations: review of previous failures and reasons for future optimism. Cancer Treat. Rev. 41 (2015), 105–113.
47. [47] Gerber, H.-P., Sapra, P., Loganzo, F., May, C., Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect?. Biochem. Pharmacol. 102 (2016), 1–6.
48. [48] Dubowchik, G.M., Firestone, R.A., Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin. Bioorg. Med. Chem. Lett., 1998, 3341–3346.
49. [49] Jain, N., Smith, S.W., Ghone, S., Tomczuk, B., Current ADC linker chemistry. Pharm. Res. 32 (2015), 3526–3540.
50. [50] Senter, P.D., Sievers, E.L., The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat. Biotechnol. 30 (2012), 631–637.
51. [51] Crisp, J.L., Savariar, E.N., Glasgow, H.L., Ellies, L.G., Whitney, M.A., Tsien, R.Y., Dual targeting of integrin αvβ3 and matrix metalloproteinase-2 for optical imaging of tumors and chemotherapeutic delivery. Mol. Cancer Ther. 13 (2014), 1514–1525.
52. [52] Dal Pozzo, A., Esposito, E., Ni, M., Muzi, L., Pisano, C., Bucci, F., Vesci, L., Castorina, M., Penco, S., Conjugates of a novel 7-substituted camptothecin with RGD-peptides as αvβ3 integrin ligands: an approach to tumor-targeted therapy. Bioconjug. Chem. 21 (2010), 1956–1967.
53. [53] Hochdörffer, K., Abu Ajaj, K., Schäfer-Obodozie, C., Kratz, F., Development of novel bisphosphonate prodrugs of doxorubicin for targeting bone metastases that are cleaved pH dependently or by cathepsin B: synthesis, cleavage properties, and binding properties to hydroxyapatite as well as bone matrix. J. Med. Chem. 55 (2012), 7502–7515.
54. [54] Dal Corso, A., Caruso, M., Belvisi, L., Arosio, D., Piarulli, U., Albanese, C., Gasparri, F., Marsiglio, A., Sola, F., Troiani, S., Valsasina, B., Pignataro, L., Donati, D., Gennari, C., Synthesis and biological evaluation of RGD peptidomimetic-paclitaxel conjugates bearing lysosomally cleavable linkers. Chem. Eur. J. 21 (2015), 6921–6929.
55. [55] Poli, G.L., Bianchi, C., Virotta, G., Bettini, A., Moretti, R., Trachsel, E., Elia, G., Giovannoni, L., Neri, D., Bruno, A., Radretumab radioimmunotherapy in patients with brain metastasis: a 124I-L19SIP dosimetric PET study. Cancer Immunol. Res. 1 (2013), 134–143.
56. [56] Heuveling, D.A., de Bree, R., Vugts, D.J., Huisman, M.C., Giovannoni, L., Hoekstra, O.S., Leemans, C.R., Neri, D., van Dongen, G.A.M.S., Phase 0 microdosing PET study using the human mini antibody F16SIP in head and neck cancer patients. J. Nucl. Med. 54 (2013), 397–401.